WO1996002566A1 - Proteine se fixant a la vitronectine - Google Patents
Proteine se fixant a la vitronectine Download PDFInfo
- Publication number
- WO1996002566A1 WO1996002566A1 PCT/SE1995/000861 SE9500861W WO9602566A1 WO 1996002566 A1 WO1996002566 A1 WO 1996002566A1 SE 9500861 W SE9500861 W SE 9500861W WO 9602566 A1 WO9602566 A1 WO 9602566A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vitronectin
- binding protein
- protein
- quinquedecapeptide
- vitronectin binding
- Prior art date
Links
- 102100035140 Vitronectin Human genes 0.000 title claims abstract description 66
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 65
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 64
- 230000027455 binding Effects 0.000 claims abstract description 36
- 108010031318 Vitronectin Proteins 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 229960005486 vaccine Drugs 0.000 claims abstract description 5
- 239000000284 extract Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 25
- 241000894006 Bacteria Species 0.000 claims description 18
- 102000018697 Membrane Proteins Human genes 0.000 claims description 16
- 108010052285 Membrane Proteins Proteins 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 230000001580 bacterial effect Effects 0.000 claims description 11
- 239000000969 carrier Substances 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 5
- 238000001261 affinity purification Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 2
- 241000295644 Staphylococcaceae Species 0.000 claims 2
- 206010041925 Staphylococcal infections Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 abstract description 8
- 230000008569 process Effects 0.000 abstract description 5
- 230000002458 infectious effect Effects 0.000 abstract description 3
- 230000000903 blocking effect Effects 0.000 abstract description 2
- 244000005700 microbiome Species 0.000 abstract description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 50
- 150000001413 amino acids Chemical group 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 21
- 229940024606 amino acid Drugs 0.000 description 21
- 239000000872 buffer Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 239000012528 membrane Substances 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 10
- 230000003993 interaction Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 108010077805 Bacterial Proteins Proteins 0.000 description 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 7
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 102000023732 binding proteins Human genes 0.000 description 7
- 108091008324 binding proteins Proteins 0.000 description 7
- 229920000669 heparin Polymers 0.000 description 7
- 229960002897 heparin Drugs 0.000 description 7
- 108010067306 Fibronectins Proteins 0.000 description 6
- 102000016359 Fibronectins Human genes 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 229920002971 Heparan sulfate Polymers 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 102000008946 Fibrinogen Human genes 0.000 description 4
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000002109 Argyria Diseases 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 108090000988 Lysostaphin Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- VCSABYLVNWQYQE-SRVKXCTJSA-N Ala-Lys-Lys Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O VCSABYLVNWQYQE-SRVKXCTJSA-N 0.000 description 1
- VCSABYLVNWQYQE-UHFFFAOYSA-N Ala-Lys-Lys Natural products NCCCCC(NC(=O)C(N)C)C(=O)NC(CCCCN)C(O)=O VCSABYLVNWQYQE-UHFFFAOYSA-N 0.000 description 1
- UCDOXFBTMLKASE-HERUPUMHSA-N Ala-Ser-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N UCDOXFBTMLKASE-HERUPUMHSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- JGDGLDNAQJJGJI-AVGNSLFASA-N Arg-Arg-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N JGDGLDNAQJJGJI-AVGNSLFASA-N 0.000 description 1
- NGTYEHIRESTSRX-UWVGGRQHSA-N Arg-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N NGTYEHIRESTSRX-UWVGGRQHSA-N 0.000 description 1
- INXWADWANGLMPJ-JYJNAYRXSA-N Arg-Phe-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CC1=CC=CC=C1 INXWADWANGLMPJ-JYJNAYRXSA-N 0.000 description 1
- UHGUKCOQUNPSKK-CIUDSAMLSA-N Asn-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N UHGUKCOQUNPSKK-CIUDSAMLSA-N 0.000 description 1
- PDECQIHABNQRHN-GUBZILKMSA-N Asp-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O PDECQIHABNQRHN-GUBZILKMSA-N 0.000 description 1
- 102100030009 Azurocidin Human genes 0.000 description 1
- 101710154607 Azurocidin Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 1
- 101710104316 Cell surface-binding protein Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- UCZXXMREFIETQW-AVGNSLFASA-N Glu-Tyr-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O UCZXXMREFIETQW-AVGNSLFASA-N 0.000 description 1
- YPHPEHMXOYTEQG-LAEOZQHASA-N Glu-Val-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCC(O)=O YPHPEHMXOYTEQG-LAEOZQHASA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CUVBTVWFVIIDOC-YEPSODPASA-N Gly-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CN CUVBTVWFVIIDOC-YEPSODPASA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- CIWILNZNBPIHEU-DCAQKATOSA-N His-Arg-Asn Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O CIWILNZNBPIHEU-DCAQKATOSA-N 0.000 description 1
- SGLXGEDPYJPGIQ-ACRUOGEOSA-N His-Phe-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)NC(=O)[C@H](CC3=CN=CN3)N SGLXGEDPYJPGIQ-ACRUOGEOSA-N 0.000 description 1
- 101000803709 Homo sapiens Vitronectin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 101710133652 Lectin-like protein Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KVNLHIXLLZBAFQ-RWMBFGLXSA-N Lys-Met-Pro Chemical compound CSCC[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N KVNLHIXLLZBAFQ-RWMBFGLXSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- YFXXRYFWJFQAFW-JHYOHUSXSA-N Phe-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N)O YFXXRYFWJFQAFW-JHYOHUSXSA-N 0.000 description 1
- KWMZPPWYBVZIER-XGEHTFHBSA-N Pro-Ser-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWMZPPWYBVZIER-XGEHTFHBSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- GXDLGHLJTHMDII-WISUUJSJSA-N Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(O)=O GXDLGHLJTHMDII-WISUUJSJSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- SYOMXKPPFZRELL-ONGXEEELSA-N Val-Gly-Lys Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N SYOMXKPPFZRELL-ONGXEEELSA-N 0.000 description 1
- KSFXWENSJABBFI-ZKWXMUAHSA-N Val-Ser-Asn Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KSFXWENSJABBFI-ZKWXMUAHSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- IOUPEELXVYPCPG-UHFFFAOYSA-N Valylglycine Chemical compound CC(C)C(N)C(=O)NCC(O)=O IOUPEELXVYPCPG-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 230000029586 bacterial cell surface binding Effects 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000010296 bead milling Methods 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- XJMXIWNOKIEIMX-UHFFFAOYSA-N bromo chloro 1h-indol-2-yl phosphate Chemical compound C1=CC=C2NC(OP(=O)(OBr)OCl)=CC2=C1 XJMXIWNOKIEIMX-UHFFFAOYSA-N 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 108010087823 glycyltyrosine Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- -1 t-butoxycarbonyl-protected amino Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010029384 tryptophyl-histidine Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56944—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the present invention relates to a vitronectin binding protein, a method for preparation thereof, a quinquedecapeptide that is useful for preparing the protein, an antibody against the protein, pharmaceutical compositions and a diagnostic or analytical kit comprising said protein, use of the protein for the preparation of a pharmaceutical composition, a diagnostic or analytical kit comprising an antibody against said protein and a method for purifying vitronectin.
- Vitronectin is a plasma protein that occurs in concentrations around 300 mg/l.
- the major part of the plasma form of vitronectin does not bind to heparin or Staphylococc s aureus .
- a denatured or immobilized form of vitronectin supports binding of heparin and S . aureus .
- S. aureus can bind to vitronectin when it is included as a stationary matrix protein. It is highly likely that blocking of S . aureus binding to vitronectin in matrix, severly hampers the infectious process.
- Extracellular matrix is composed of a complex mixture of macromolecules that serve as a substrate for cellular adhesion.
- Many potentially pathogenic staphylococcal strains have the ability to bind to ECM proteins such as fibronectin [1, 2], collagen [3, 4, 5], laminin [6], fibrinogen [7] and vitronectin (Vn) [8, 9], as well as heparan sulphate glycosaminoglycans [10] presented in ECM and on eukaryotic cell surface.
- Bacteria possess specific binding molecules which interact with distinct sites of the proteins in the ECM of the host [11]. It has been shown earlier that this adherence is of vital importance for the infectious process. Thus these binding functions are suitable targets for antimicrobial therapy and prophylactic treatment.
- Another procedure for its purification is based on an FPLC Mono-Q column to separate the staphylococcal cell surface proteins, and to obtain the 60 kDa bacterial protein retaining Vn-binding ability.
- a 60 kDa protein that bind to vitronectin is already known [9]. However the protein has neither been purified nor characterized.
- bacteria colonise body sites by sequentially engaging their surface-bound adhesins with specific substances availabe on epithelial cells, endothelial cells, leukocytes, or the ECM. It is generally accepted that this recognition process is required to establish bacteria at a given site. Aside from the ability to recognise a host component, these binding proteins play a substantial role in determining the outcome of the host-parasite interacion. They may initiate invasion by the pathogen, either themselves or by engaging a cascade of secondary molecules. Undoubtedly many bacterial cell surface binding proteins have not yet been discovered, identified, isolated or characterized.
- the present invention provides both a new protein that binds to vitronectin and a new quinquedecapeptide that is derived from the heparin binding domain of vitronectin.
- the quinquedecapeptide constitutes the vitronectin region that is responsible for binding the new protein.
- a first aspect of the invention consists of a vitronectin binding protein having an apparent molecular weight of 60 kDa and having affinity to the quinquedecapeptide AKKQRFRHRNRKGYR and having the N-terminal sequence MNKTDLINAVAEVADLVGKV, or variants, subfragments, multiples or mixtures thereof.
- a part of the vitronectin binding region of the protein has been found to be encoded by the nucleotide sequence 5'- CCCTCAACTGTTTCAAACAATATAATTGATGAACTTAAACAAGTTGG TGAATACAATCAAATTTTCACAACTGAAGTTGACGGTACAGTCATAAACAATTTATGT AAATNCAAAATGCCAAGAAGACATTGGATTACTTCCATTGCTTCTTGGCATTTTTTCA GGG -3'. With the reading frame begining at the first nucleotide this corresponds to the amino acid sequence
- nucleotide sequence is an unidentified nucleotide, corresponding to X in the amino acid sequence, which is an unidentified amino acid.
- the four possible nucleotides give the four possible amino acids: phenylalanine, serine, tyrosine or cysteine. A clone was obtained and the nucleotide sequence was determined according to the general method described in K. Jacobsson and L. Frykberg, 1995, BioTechniques, Cloning of Ligand-Binding Domains of Bacterial Receptors by Phage Display, Vol. 18. No. 5, pages 878-885.
- subfragment in the description and claims meant a part- fragment of the given domains or fragments which include parts from the various domains having mutually the same binding properties.
- variant in the desciption and claims meant proteins or peptides in which the original amino acid sequence has been modified or changed by insertion, addition, substitution, inversion or exclusion of one or more amino acids, although while retaining or improving the binding properties, also including functional derivatives.
- the invention also relates to those proteins which contain several arrays (multiples) of the binding domains or mixtures of the binding domains with retained binding properties.
- the invention also relates to mixtures of the various domains of amino acid sequences having mutually the same binding properties.
- a second aspect of the invention consists of a method for preparing a vitronectin binding protein according to the first aspect. This can be done by a method comprising culturing a staphylococcal bacterial strain, preferably Staphylococcus aureus. strain V8, preparing a cell surface protein extract of the bacteria and either applying said extract to an affinity purification step using the peptide AKKQRFRHRNRKGYR or applying said extract to an ion-exchange purification step. From a culture of 100 ml 0.2 g protein extract of cell wall proteins was obtained and therefrom 2-3 ⁇ g of the protein according to the invention was obtained, as in the Examples described below.
- bacteria than S. aureus can be used for the production of the protein, such as other bacteria from the genus Staphylococcus ⁇
- Various media can be used, such as Brain-Heart Infusion, Luria Broth or Todd-Hewitt Broth (THB) .
- a preferred medium is especially THB.
- the medium used should preferably be a rich and complex medium.
- the bacteria can be grown at temperatures between 33 and 42°C, preferably between 35 and 39°C and most preferably at 37°C.
- the pH is suitably ranging from 6.7 to 7.8, preferably from 7.0 to 7.5 and most preferably the culture is performed at the physiological pH, which is 7.3.
- enzymatic digestion can be used.
- the protein according to the invention may also be produced by cultivation of a genetically engineered host, e. g. E. coli, that has been provided with the gene for the protein of the invention.
- the protein may be provided as an extracellular or intracellular protein.
- An alternative to removing the protein from the cell surface is to disintegrate the cells and then clarifying the disintegrate by for example centrifugation, filtration or extraction.
- the disintegration can be performed by chemical methods using for example lysozymes, lysostaphin, alkalis, solvents or surfactants, physical methods such as osmotic shock, drying or freeze-thawing, mechanical methods such as high pressure, bead milling or ultrasonication.
- lysostaphin In a preferred method for disintegration lysostaphin is used.
- the method described in Example 2 below can be altered by substituting one or more steps or adding one or more steps by one or more of the following steps: precipitation, extraction of different kinds, adsorption, isoelectric focusing and evaporation.
- precipitation As further alternatives to the chromatography mehods described in Example 3 and 4 below can be mentioned gel filtration, reverse phase HPLC, hydrofobic chromatography etc.
- a third aspect of the invention consists of the quinquedecapeptide AKKQRFRHRNRKGYR or a variant thereof, a pharmaceutical composition comprising an effective amount of said quinquedecapeptide or a variant thereof and pharmaceutically acceptable excipients, diluents and carriers.
- the excipients, diluents and carriers may include all known agents suitable for use as such in lotions, pastes, creams, ointments, rinsing fluids, e.g. for use in the eyes or in the nose, and other compositions for topical use.
- the composition may also be administered rectally or on a plaster.
- additives and administration forms are not to be understood as limiting, but merely illustrative.
- a purpose with the third aspect is to inhibit bacterial adhesion to stationary vitronectin in connection with infections.
- the aspect defines a peptide that can be used for such a purpose.
- a fourth aspect of the invention consists of an antibody, such as a monoclonal or polyclonal antibody, against a vitronectin binding protein according to the first aspect.
- the antibodies could be produced by immunizing an animal, e. g. as in Example 8 a rat, by administration of the protein of interest. It is well known how to immunize an animal with an antigen, in this case the protein according to the invention, collect the blood, isolate the serum and use the antibodies that react with the protein.
- monoclonal antibodies could be produced by a) immunizing mice with the protein according to the invention, and further by a method known per se b) isolating a lymphocyte mixture from the mice, c) fusing B-lymphocytes with B-myeloma mouse cells to produce a hybridoma, d) transferring the mixture of produced hybridomas and non- hybridized B-myeloma cells to a culture medium for the produced hybridomas, and cultivating and selecting the produced hybridomas over the non-hybridized B-myeloma cells, e) subcloning the hybridoma that produces the antibody that is directed specifically against the protein according to the invention, and at will f) isolating the antibody.
- the antibody according to the invention can be used in a diagnostic or analytical kit as described below. They can also be used as a prophylactic or therapeutic agent for e.g. intravenous, intramuscular or subcutaneous administration. Administered in this way, the antibodies according to the invention can provide passive immunization to the organism being treated.
- the third and fourth aspects concern providing means to inhibit the in vivo invasion of the human or animal body, of particularly S . aureus , although other microbial infections where the microbe binds to vitronectin are included in the invention.
- Many micoorganisms do bind to vitronectin when initiating invasion of an organism.
- Those microbes may interact with the quinquedecapeptide according to the third aspect and the interaction of such microbes with the substances according to the invention is therefore included in the invention. All such microorganisms could also cross-react with the antibodies according to the fourth aspect of the invention.
- these aspects concern all pathogens that interact with vitronectin.
- a fifth aspect of the invention consists of a pharmaceutical composition comprising an effecive amount of a vitronectin binding protein according to the first aspect and pharmaceutically acceptable excipients, diluents or carriers, and a vaccine composition comprising an effecitive amount of a vitronectin binding protein according to the first aspect, and possibly pharmaceutically acceptable adjuvants and excipients.
- the excipients, diluents and carriers for the pharmaceutical composition may include all known agents suitable for use as such in lotions, pastes, creams, ointments, rinsing fluids, e.g. for use in the eyes or in the nose, and other compositions for topical use.
- the composition may also be administered rectally or on a plaster.
- Suitable adjuvants are those conventionally used in the field.
- suitable excipients are annitol, lactose, starch, cellulose, glucose etc., only to mention a few. The examples given are not to be regarded as limiting the invention.
- a purpose with the fifth aspect is to competitively inhibit the adhesion of bacteria.
- the pharmaceutical composition can be applied locally or adminstered intravenously, intramuscularly, subcutaneously, etc. to inhibit bacterial invasion.
- the vaccine can be used to immunize a mammal including the human body, or other vertebrates.
- a sixth aspect of the invention consists of a diagnostic or analytical kit comprising a vitronectin binding protein according to the first aspect or the quinquedecapeptide according to the third aspect, or a diagnostic or analytical kit comprising an antibody.
- the kit may for instance be used for assaying antibodies against the VnBP according to the first aspect. In this way it could be indicated that the organism has been infected with the bacteria of interest, or that the organism has sufficient immunological protection against future infections. For example it is possible to determine if a pregnant woman has antibodies enough to protect her baby from such an infection. Various samples could also be assayed for the presence of the VnBP according to the first aspect. Antibodies or the quinquedecapeptide can be used for this purpose. In the kit serum or solutions containing the protein according to the first aspect may be present for use as a standard.
- a seventh aspect of the invention consists of a method for purifying vitronectin by using immobilized vitronectin binding protein in an affinity column.
- Vitronectin is unstable and difficult to purify, e. g. because of its high molecular weight and the fact that it tends to aggregate. With this aspect of the invention vitronectin could be produced more easily and cheaper.
- Fig. 1 represents the isolation of a bacterial protein recognising the quinquedecapeptide.
- a 60 kD staphylococcal protein was isolated using a peptide affinity column.
- Left lane shows molecular weight markers.
- Fig. 2 illustrates the separation of staphylococcal cell surface proteins using FPLC on a Mono-Q column.
- the putative vitronectin- binding protein was indicated as VnBP.
- Fig. 3 represents the results of SDS-PAGE and western blot analysis of the putative VnBP.
- Lane a molecular weight markers
- Lane b silver staining of the fraction having the ability to bind immobilised Vn, revealing a single band having a molecular mass of 60 kDa.
- the protein transblotted onto a nitrocellular membrane was able to bind soluble Vn, which was subsequently detected using rabbit anti-Vn polyclonal antibodies (lane c) , or monoclonal antibody against Vn (lane d) .
- Lanes e and f were respective controls when Vn was ommitted.
- Fig. 4 represents the detection of the putative VnBP from the staphylococcal cell surface protein extract.
- Lane a the LiCl- extract profile was stained with Coomassie Blue on a nitrocellular membrane after SDS-PAGE separation;
- Lane b the separated proteins were probed with Vn and was subsequently detected using rabbit anti-Vn polyclonal antibodies;
- Lane c control experiment of the rabbit antibodies when Vn was ommitted;
- Lane d high concentration of normal rabbit serum (1:200) was used to detect staphylococcal protein A (SpA) from the strain V8.
- SpA staphylococcal protein A
- Fig. 5 illustrates the effects of synthetic peptides on binding of ⁇ H-labelled S . aureus cells to immobilised Vn, fibronectin or fibrninogen on microtiter plates. The results of the peptide competition are expressed as relative inhibition compared with a PBS control. 15-mer: quinquedecapeptide; 13-mer: tridecapeptide.
- Fig. 6 illustrates the detection of the putative VnBP using a microtiterplate assay. Captured bacterial protein by immobilised Vn on the microtiterplates was detected using rat antibodies against the LiCl-protein extract, which was then probed with secondary antibodies against rat Igs.
- Staphylococcus aureus prototype strain V8 a well-known protease producer, was obtained from Dr. Staffan Arvidsson, Karolinska Institute, Sweden. The bacteria were grown in Todd- Hewitt Broth (THB) (Difco, Detroit, MI, USA) with 100 ml inoculum in 2 liter flasks at 37°C for 20 h on a gyratory shaker (New Brunswick, USA) with vigorous agitation [12]. Bacterial cells were harvested at the late stationary phase by centrifugation (5,000 X g for 30 min at 4°C) and washed twice with 0.1 M phosphate buffer saline (PBS, pH 7.0). All common chemicals were of analytical grade, purchased from KEBO (Spanga, Sweden) .
- LiCl-extract of staphylococcal cell surface protein was prepared as described elsewhere [10]. Briefly, every 1 g of bacteria was resuspended in 5 ml 1 M LiCl and the mixture was incubated at 37°C for 2 h on a gyratory shaker (New Brunswick, USA) with vigorous agitation. After centrifugation (5000 x g for 15 min at 4°C) sedimenting the bacteria, the supernatant was dialysed (membrane tubing MWCO: 12- 14 000, Spectrum Medical Industries Inc., Los Angeles, CA, USA) against 0,02 M Tris-HCl buffer pH 9.0 over night to remove LiCl.
- the sample was centrifuged (5000 x g for 15 min at 4 °C) , and the protein concentration in the clear supernatant was determined using Bio-Rad protein assay. The extract was then stored at -20°C as 2 ml aliquots.
- VnBP was purified on a HiTrap NHS column (Pharmacia) coupled to the quinquedecapeptide (AKKQRFRHRNRKGYR) comprising the heparin binding consensus sequence of human vitronectin.
- the VnBP purified this way is shown in Figure 1.
- Bacterial protein recognising the synthetic peptide (Ala ⁇ '-Arg ⁇ 0 *) was isolated by the following procedure.
- HiTrapTM N-hydroxysuccinimide (NHS)-activated affinity columns were purchased from Pharmacia, Uppsala, Sweden. Five milligrams of the synthetic peptide was used to couple to a 1 ml column followed by washing and deactivation according to the manufacturer's instruction. Coupling efficiency was generally higher than 85%. About 20 ml LiCl-extract containing approximately 2 mg protein (Bio-Rad protein assay) was applied to the peptide-column through a P-3 peristaltic pump (Pharmacia) , followed by equilibration with PBS at 4°C.
- Staphylococcal cell surface proteins were separated using FPLC on
- the chromatography procedure was as follwed: 5 min buffer A equilibration, 4 min sample loading onto the Mono-Q column, again 5 min buffer A returning to base-line, 30 min gradient 0-70 % buffer B, 10 min gradient 70-77.5 % buffer B, 13 min gradient 77.5-100 % buffer B, 5 min 100 % buffer B, and 2 min 100 % buffer A.
- a 10-ml super-loading loop (Pharmacia) was used with 20 min sample loading time, and the protein separation pattern was proved to be reproducible.
- FIG. 2 A separation profile of an LiCl-extract of S . aureus is shown in Fig. 2.
- the chromatography achieved optimal resolution of a number of bacterial proteins from staphylococcal cell surface. Occasionally some peaks drifted earlier or later with a margin of 1-2 min (0,5-2 ml). In both our pilot experiments and later scale-up runs the chromatogram was proved to be easily reproducible, and was therefore complementary to the SDS-PAGE profile of the staphylococcal cell surface proteins published previously [10]. As such there has been developed a convenient, inexpensive and reliable method to release and analyze bacterial cell surface proteins, many of which are yet to be identified and characterized.
- Human Vn was purified as described by Yatohgo et al [16]. The purified preparation was homogeneous as judged by SDS-PAGE (two bands corresponding to 65 and 75 kDa) and western blot analysis with mouse anti-human Vn monoclonal antibody (Boehringer Mannheim GmbH, Germany) and did not cross-react with antibodies against fibronectin.
- the LiCl-protein extract was separated using the Mini-PROTEAN II cell (Bio-Rad) with 4% stacking gel and 7.5% separating gel. In western blot experiments, the separated protein was tranferred to nitrocellulose membranes (Schleicher & Schuell) at 65°C for 30 min following SDS-PAGE.
- the membranes were blocked with 3% BSA in PBS for aproximatly 3h at room temperature, and then incubated with 5 ⁇ g/ml Vn in PBST for 1 h at room temperature.
- the membranes were then incubated with 5 ⁇ g/ml rabbit anti-Vn polyclonal antibodies (Calbiochem) or monoclonal antibody aganist Vn (Boehringer Mannheim Biochemica) in PBS for 1 h at room temperature with gentle agitation. Secondary antibodies against rabbit or mouse Igs conjugated with alkaline phosphatase in 1:1000 dilution were added to the membranes.
- the membranes were developed with bromochloroindolyl phosphate/nitro blue tetrazolium (Bio-Rad) according to the manufacturers' recomendation. Between each step the membranes were washed twice with 5 ml PBST for 5 min. As shown in Fig. 3, a single protein band having a molecular mass of 60 kDa was revealed after silver staining (lane b) , and in the western blot experiments.
- This protein transblotted onto a nitrocellular membrane, had the ability to bind soluble Vn at a concentration of 5 ⁇ g/ml in PBS, which was subsequently detected using either rabbit anti-Vn polyclonal antibodies or monoclonal antibody directed against Vn (lane c and e) .
- Control experiments with both anti-Vn mentioned above, omitting Vn were performed (lane d and f) .
- an LiCl-extract transblotted onto a nitrocellular membrane was stained with Coomassie blue (Fig. 4, lane a).
- aureus strain V8 the strain employed in the present study, has a novel structure lacking an IgG-binding domain (58 amino acid) and two octapeptide repetitions located in the membrane attaching region.
- IgG-binding domain 58 amino acid
- two octapeptide repetitions located in the membrane attaching region.
- staphylococcal protein A from the strain V8 having a molecular mass slightly above 45 kDa (lane d) , which coincided with published data [13].
- lane d staphylococcal protein A from the strain V8 having a molecular mass slightly above 45 kDa
- Amino acid analysis was performed as follows. About 50 ⁇ g of the purified 60 kDa Vn-binding protein was hydrolyzed with 6 M HC1 containing 2 mg/ml phenol for 24 h at 110°C. The amino acid composition was determined by the Protein and Peptide Unit at the Deptartment of Medical Biochemistry and Biophysics, Karolinska Institute, Sweden. Approximately 1.5 nmol purified protein was used for N-terminal sequence determination after methanolic HCl de-blocking treatment [18]. Briefly, the protein sample was dissolved in 1 N HCl in anhydrous methanol and the mixture was incubated at 37°C for 5 h followed by dialysis against deionized water overnight at 4°C and lyophilization. The freeze-dried sample was dissolved in 30 % Acetonitrile and sequencing was performed by the Biomolecular Resource Facility at Lund University, Lund, Sweden.
- S . aureus has the ability to bind to heparin and heparan sulphate [10].
- a heparin binding protein was purified from an S . aureus extract by passing it through a heparin column. The purified protein was subjected to N-terminal amino acid analysis according to Example 6, and as shown in Table II the heparan sulphate binding protein and the VnBP seem to be the same protein.
- Antibodies aganist the LiCl-extract were produced in Wistar rats according to standard methods. Briefly, each of four rats was immunized with 100 ⁇ g staphylococcal protein extract subcutaneously at three occasions with a three-week span in between. The antigens were given with Freund's complete adjuvant (Sigma) at the first and with incomplete adjuvant (Sigma) at the following two injections. The antibody titer aganist the LiCl- extract was monitered using ELISA on microtiterplates coated with the bacterial protein extract and detected using anti-rat Igs conjugated with horseradish peroxidase (The Binding Sites, Birmingham, UK) as secondary antibodies. The rat sera were pooled and stored at -20°C as 0.5 ml aliquots.
- a 15 amino acid long peptide (Ala-* 4 '-Arg-'" 1 ) was synthesised using t-butoxycarbonyl-protected amino acids with an automated peptide synthesiser (model 430A, Applied Biosystems, Inc.), and was subsequently purified on FPLC.
- the amino acid sequence of the synthetic peptide was determined according to the manufacturer's instructions from Applied Biosystems.
- a 13 amino acid long peptide (Asn ⁇ ' ⁇ -Leu ⁇ ") was kindly provided by Dr. W. St ⁇ ber (Behringwerke. Marburg, Germany) .
- Microtiter plates (96-well) (Costar, Cambridge, MA, USA) were coated with 0.2 ⁇ g/well of Vn 1 preparation, fibronectin (Sigma Chemical Co) of fibrinogen (Kabi, Sweden) in lOO ⁇ l PBS overnight at 4"C and additional binding sites were blocked using 3% BSA in PBS containing 0.05% Tween-20 for 2 h at 37 * C, similar to a published procedure [17].
- Fifty microliter of ⁇ H-labelled bacteria (approximately 5 x 10"
- VnBP vitronectin binding protein
- the plates were developed with 1.2- phenylendiamine (DAKO, Glostrup, Denmark) in 0.1 M citric acid- phosphate buffer pH 5.0 and approximately 0.01% hydrogen peroxide (KEBO) as recomended by the manufacturer.
- the plates were read at 490 nm with a Bio-Rad ELISA reader. Several repetitions of duplicate determinations were made and averaged in all cases.
- MOLECULE TYPE protein
- HYPOTHETICAL NO
- FRAGMENT TYPE N-terminal
- ORGANISM Staphylococcus aureus
- MOLECULE TYPE DNA (genomic)
- HYPOTHETICAL NO
- ANTI-SENSE NO
- ORGANISM Staphylococcus aureus
- ORGANISM Staphylococcus aureus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8504958A JPH10505581A (ja) | 1994-07-15 | 1995-07-14 | ビトロネクチン結合タンパク質 |
EP95926088A EP0776336A1 (fr) | 1994-07-15 | 1995-07-14 | Proteine se fixant a la vitronectine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9402490A SE9402490D0 (sv) | 1994-07-15 | 1994-07-15 | Vitronection binding protein |
SE9402490-8 | 1994-07-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996002566A1 true WO1996002566A1 (fr) | 1996-02-01 |
WO1996002566A9 WO1996002566A9 (fr) | 1997-02-13 |
Family
ID=20394737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1995/000861 WO1996002566A1 (fr) | 1994-07-15 | 1995-07-14 | Proteine se fixant a la vitronectine |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0776336A1 (fr) |
JP (1) | JPH10505581A (fr) |
SE (1) | SE9402490D0 (fr) |
WO (1) | WO1996002566A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060852A1 (fr) * | 2000-02-17 | 2001-08-23 | Biostapro Ab | Une proteine 52 kda derivee de staphylocoque a coagulase negative et des fragments de celle-ci |
AU2001242392B2 (en) * | 2000-02-15 | 2005-02-10 | Tiense Suikerraffinaderij N.V. | Inulin products with improved nutritional properties |
US7834151B2 (en) * | 1997-11-26 | 2010-11-16 | The Texas A&M University System | SDRD protein from Staphylococcus aureus and diagnostic kits including same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994006830A1 (fr) * | 1992-09-21 | 1994-03-31 | Alfa-Laval Agri International Aktiebolag | Proteine de liaison du fibrinogene |
WO1994018327A1 (fr) * | 1993-02-05 | 1994-08-18 | Smithkline Beecham Plc | Proteine de liaison de fibronectine, anticorps monoclonal et leur utilisation pour prevenir l'adherence bacterienne |
-
1994
- 1994-07-15 SE SE9402490A patent/SE9402490D0/xx unknown
-
1995
- 1995-07-14 WO PCT/SE1995/000861 patent/WO1996002566A1/fr not_active Application Discontinuation
- 1995-07-14 EP EP95926088A patent/EP0776336A1/fr not_active Withdrawn
- 1995-07-14 JP JP8504958A patent/JPH10505581A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994006830A1 (fr) * | 1992-09-21 | 1994-03-31 | Alfa-Laval Agri International Aktiebolag | Proteine de liaison du fibrinogene |
WO1994018327A1 (fr) * | 1993-02-05 | 1994-08-18 | Smithkline Beecham Plc | Proteine de liaison de fibronectine, anticorps monoclonal et leur utilisation pour prevenir l'adherence bacterienne |
Non-Patent Citations (2)
Title |
---|
BIOCHIMICA ET BIOPHYSICA ACTA, Volume 1225, 1993, OLIN D. LIANG et al., "Multiple Interactions Between Human Vitronectin and Staphylococcus Aureus", pages 57-63. * |
THE JOURNAL OF CELL BIOLOGY, Volume 121, No. 2, April 1993, BRUCE E. VOGEL et al., "A Novel Integrin Specificity Exemplified by Binding of the alfa v beta 5 Intergrin to the Basic Domain of the HIV Tat Protein and Vitronectin", pages 461-468. * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7834151B2 (en) * | 1997-11-26 | 2010-11-16 | The Texas A&M University System | SDRD protein from Staphylococcus aureus and diagnostic kits including same |
AU2001242392B2 (en) * | 2000-02-15 | 2005-02-10 | Tiense Suikerraffinaderij N.V. | Inulin products with improved nutritional properties |
WO2001060852A1 (fr) * | 2000-02-17 | 2001-08-23 | Biostapro Ab | Une proteine 52 kda derivee de staphylocoque a coagulase negative et des fragments de celle-ci |
Also Published As
Publication number | Publication date |
---|---|
SE9402490D0 (sv) | 1994-07-15 |
EP0776336A1 (fr) | 1997-06-04 |
JPH10505581A (ja) | 1998-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Boulnois | Pneumococcal proteins and the pathogenesis of disease caused by Streptococcus pneumoniae | |
FI102768B (fi) | Hybridi-DNA-molekyyli ja menetelmä fibronektiiniä sitovan proteiinin v almistamiseksi | |
Courtney et al. | Cloning, sequencing, and expression of a fibronectin/fibrinogen-binding protein from group A streptococci | |
Leppla | Large-scale purification and characterization of the exotoxin of Pseudomonas aeruginosa | |
Ben Nasr et al. | Human kininogens interact with M protein, a bacterial surface protein and virulence determinant | |
US5776712A (en) | Methods and materials for the detection of Staphylococcus aureus | |
US6291654B1 (en) | Method for isolating a C3 binding protein of streptococcus pneumoniae | |
US5440014A (en) | Fibronectin binding peptide | |
Yu et al. | The interaction between human transferrin and transferrin binding protein 2 from Moraxella (Branhamella) catarrhalis differs from that of other human pathogens | |
WO1998021337A9 (fr) | Proteine de liaison c3 de streptococcus pneumoniae | |
US5413918A (en) | Gene and method for production of a 40-45-kDa IgA binding protein | |
JP4173549B2 (ja) | コアグラーゼ陰性ブドウ球菌に由来する、新規フィブリノーゲン結合たん白質 | |
CZ2001951A3 (cs) | Prostředky obsahující streptokokový Cbeta protein | |
Liang et al. | Isolation and characterisation of a vitronectin-binding surface protein from Staphylococcus aureus | |
WO1987007146A1 (fr) | INHIBITEUR DE L'ACTIVITE DE LA CHEMOTAXINE C5a | |
AU678362B2 (en) | Antibiotic cryptdin peptides and methods of their use | |
Calderone et al. | Adherence moleculaes of Candida albicans | |
WO1996002566A1 (fr) | Proteine se fixant a la vitronectine | |
WO1994013310A9 (fr) | Proteine de liaison de sialoproteine osseuse et son procede de preparation | |
WO1996002566A9 (fr) | Proteine se fixant a la vitronectine | |
WO1994013310A1 (fr) | Proteine de liaison de sialoproteine osseuse et son procede de preparation | |
KR19990071959A (ko) | 말라세지아에서 유래된 항원성 단백질 | |
Clyne et al. | Characterization of staphylococcal λ-lysin | |
CA2277554C (fr) | Mutants de streptokinase | |
Glurich et al. | Identification of Streptococcus pyogenes proteins that bind to rabbit kidney in vitro and in vivo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1995926088 Country of ref document: EP |
|
COP | Corrected version of pamphlet |
Free format text: PAGE 1/3,DRAWINGS,REPLACED BY CORRECT PAGE 1/3 |
|
WWP | Wipo information: published in national office |
Ref document number: 1995926088 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1997 776278 Date of ref document: 19970612 Kind code of ref document: A Format of ref document f/p: F |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995926088 Country of ref document: EP |